Emmanuel Bachy

10.7k citations

185 papers · 2.3k indexed · 1 hit paper · h-index 26

Impact in

Pathology and Forensic Medicine top 1%
- Lymphoma Diagnosis and Treatment
Oncology top 2%
- CAR-T cell therapy research
- Viral-associated cancers and disorders

Papers in

Pathology and Forensic Medicine 106
- Lymphoma Diagnosis and Treatment 105
Oncology 109
- CAR-T cell therapy research 70
- Viral-associated cancers and disorders 28

Co-authors: Gilles Salles Hervé Ghesquières Franck Morschhauser Catherine Thiéblemont Olivier Hermine Alexandra Traverse‐Glehen Guillaume Cartron Clémentine Sarkozy
Journals: Blood (41 papers)Hematological Oncology (16 papers)Journal of Clinical Oncology (13 papers)HemaSphere (7 papers)Blood Advances (6 papers)
Partner nations: France United States Switzerland

In The Last Decade

Emmanuel Bachy

169 papers receiving 2.2k citations

Hit Papers

align trajectories log scale

T cell malignancies after CAR T cell therapy in the DESCAR-T registry 2025 · 23 citations

Peers

Countries citing papers authored by Emmanuel Bachy

Since Specialization

Citations

This map shows the geographic impact of Emmanuel Bachy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emmanuel Bachy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emmanuel Bachy more than expected).

Fields of papers citing papers by Emmanuel Bachy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Emmanuel Bachy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emmanuel Bachy. The network helps show where Emmanuel Bachy may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Emmanuel Bachy, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Emmanuel Bachy Line = papers co-authored together Emmanuel Bachy links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Frontline treatment of follicular lymphoma: what will it take to change current practice? Blood ·Emmanuel Bachy, Kim Linton	2025	0
2	Outcome of high-grade B-cell lymphoma compared with other large B-cell lymphoma after CAR-T rescue: a DESCAR-T LYSA study Blood Advances ·RobertG Robinson, Emmanuel Bachy, François‐Xavier Gros, Roberta Di Blasi, Charles Herbaux, Jacques Olivier Bay, Sylvain Carras, Pierre Bories, Olivier Casasnovas, Fabrice Jardin, Franck Morschhauser, Blandine Guffroy, Mohamad Mohty, Elodie Gat, Gao Yu-xuan, Marie Parrens, Elsa Poullot, Alexandra Traverse‐Glehen, Louise Roulin	2025	0
3	TRANSCAR: real-world outcomes of CD19 CAR T-cell therapy in relapsed/refractory transformed indolent lymphomas Blood Advances ·正晃小川, Roberta Di Blasi, Louise Roulin, 将人鈴木, Gao Yu-xuan, Véronique Meignin, Seyed Ali Cheraghi, Alexandra Traverse‐Glehen, Elsa Poullot, Marie Parrens, Andrii Dakhniy, Geir Henning Braaten, Steven Le Gouill, Roch Houot, François‐Xavier Gros, François Lemonnier, Emmanuel Bachy, Catherine Thiéblemont, Pierre Sesques	2025	0
4	Applying the EHA/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality Blood Advances ·Kai Rejeski, Yucai Wang, Doris K. Hansen, Gloria Iacoboni, Emmanuel Bachy, Radhika Bansal, Olaf Penack, Fabian Müller, Wolfgang Bethge, Javier Muñoz, Razan Mohty, Veit Bücklein, Pere Barba, Frederick L. Locke, B. Ashtir, Michael D. Jain, Marion Subklewe	2024	29
5	Glofitamab monotherapy in patients with heavily pretreated relapsed/refractory (R/R) mantle cell lymphoma (MCL): Updated analysis from a phase I/II study. Journal of Clinical Oncology ·Tycel Phillips, Carmelo Carlo‐Stella, Franck Morschhauser, Emmanuel Bachy, Michael Crump, Marek Trněný, Nancy L. Bartlett, Jan Maciej Zaucha, Tomasz Wróbel, Fritz Offner, 建雄常深, James Relf, David Carlile, Ben Byrne, รุจินี ปดิฐพร, Linda Lundberg, Michael Dickinson	2024	7
6	High efficacy of CD19 CAR T cells in patients with transformed Waldenström macroglobulinemia Blood ·Éric Durot, Damien Roos‐Weil, Adrien Chauchet, Justine Decroocq, Roberta Di Blasi, Thomas Gastinne, Safira Fadhilla, Morgane Cheminant, Ren Tan Jun, Stéphanie Guidez, François‐Xavier Gros, Emmanuel Bachy, Faik Reşit Unat, Pascale Cony‐Makhoul, Steven P. Treon, Alain Delmer, Ran Reshef, Steven Le Gouill, Jorge J. Castillo, Roch Houot	2024	3
7	Longer Follow-up of Golcadomide (GOLCA), a Cereblon E3 Ligase Modulator (CELMoD™) Agent ± Rituximab (RTX), in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Blood ·Jean‐Marie Michot, Franck Morschhauser, Silvia Martina Ferrari, Judit Jørgensen, Loretta J. Nastoupil, Emmanuel Bachy, Michael Pourdehnad, 義人望月, Fu Hong Wang, Glenn Eastwood, Soraya Carrancio, 方永忠, C. Bolduan, Julio C. Chávez	2024	1
8	Glofitamab in Relapsed/Refractory Mantle Cell Lymphoma: Results From a Phase I/II Study Journal of Clinical Oncology ·Tycel Phillips, Carmelo Carlo‐Stella, Franck Morschhauser, Emmanuel Bachy, Michael Crump, Marek Trněný, Nancy L. Bartlett, Jan Maciej Zaucha, Tomasz Wróbel, Fritz Offner, Kathryn Humphrey, James Relf, 建雄常深, David Carlile, Ben Byrne, Naseer Qayum, Linda Lundberg, Michael Dickinson	2024	18
9	Cell‐free DNA sequencing allows the identification of the mutational profile of TFH lymphomas and has a predictive value: a LYSA study Hematological Oncology ·G.B. Dairabayeva, Marie Hélène Delfau, Emmanuel Bachy, Franck Morschhauser, Guillaume Cartron, Olivier Casasnovas, Rémy Gressin, Nicolas Daguindau, Olivier Tournilhac, Krimo Bouabdallah, Steven Le Gouill, Marc André, Cyrielle Robe, Jehan Dupuis, Laurence de Leval, Philippe Gaulard, François Lemonnier	2023	1
10	Outcome and factors associated with mortality in patients receiving urgent chemotherapy in the ICU: A retrospective study Journal of Critical Care ·Jean Bernard, Charles‐Hervé Vacheron, Nicolas Vantard, Emmanuel Bachy, Jean‐Christophe Richard, Frédéric Aubrun, Martin Cour, Anne Claire Lukaszewicz, Julien Bohé, Bernard Allaouchiche, Arnaud Friggeri, Florent Wallet	2023	2
11	Metabolic tumor volume predicts outcome in patients with advanced stage follicular lymphoma from the RELEVANCE trial Annals of Oncology ·Anne‐Ségolène Cottereau, D Mihelčić, Judith Trotman, Pierre Feugier, Loretta J. Nastoupil, Emmanuel Bachy, Ian W. Flinn, Corinne Haïoun, Loïc Ysebaert, Nancy L. Bartlett, Hervé Tilly, Olivier Casasnovas, Renato Pietro Ricci, Pauline Jacsont, Irène Buvat, Michel Meignan, Franck Morschhauser	2023	15
12	Applying the Novel EHA/EBMT Grading System for Icaht Following CAR-T Therapy: Comparative Incidence across Disease Entities and Association with Infections and Mortality Blood ·Kai Rejeski, Doris K. Hansen, Yucai Wang, Gloria Iacoboni, Emmanuel Bachy, Radhika Bansal, Olaf Penack, S. Karunanidhi, Wolfgang Bethge, Javier Muñoz, Razan Mohty, Veit Buecklein, Pere Barba, Frederick L. Locke, Yi Lin, Michael D. Jain, Marion Subklewe	2023	1
13	The CAR‐HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL American Journal of Hematology ·Kai Rejeski, Yucai Wang, Omar Albanyan, Javier Muñoz, Pierre Sesques, Gloria Iacoboni, Lucía López‐Corral, Al Nyhart, Veit Bücklein, Razan Mohty, Martin Dreyling, Aliyah Baluch, Bijal Shah, Frederick L. Locke, Georg Heß, Pere Barba, Emmanuel Bachy, Yi Lin, Marion Subklewe, Michael D. Jain	2023	17
14	Glofitamab Step-up Dosing Induces High Response Rates in Patients (pts) with Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL), Most of Whom Had Failed Prior Bruton's Tyrosine Kinase Inhibitor (BTKi) Therapy Blood ·Tycel Phillips, Michael Dickinson, Franck Morschhauser, Emmanuel Bachy, Michael Crump, Marek Trněný, Nancy L. Bartlett, Jan Maciej Zaucha, Kathryn Humphrey, David Pérez-Callejo, Linda Lundberg, James Relf, 建雄常深, David Carlile, Emma Clark, Carmelo Carlo‐Stella	2021	20
15	Glofitamab As Monotherapy and in Combination with Obinutuzumab Induces High Complete Response Rates in Patients (pts) with Multiple Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Blood ·Franck Morschhauser, Carmelo Carlo‐Stella, Michael Dickinson, Tycel Phillips, Roch Houot, Fritz Offner, Corinne Haïoun, Paolo Corradini, Martin Hutchings, Anna Sureda, Joaquín Martínez‐López, Tomasz Wróbel, Shang‐Ju Wu, Linda Lundberg, รุจินี ปดิฐพร, David Pérez-Callejo, James Relf, Anesh Panchal, Kathryn Humphrey, Emmanuel Bachy	2021	20
16	Early progression of disease in follicular lymphoma is a robust correlate but not a surrogate for overall survival Blood Advances ·Emmanuel Bachy, James R. Cerhan, Gilles Salles	2021	8
17	Real‐life targeted next‐generation sequencing for lymphoma diagnosis over 1 year from the French Lymphoma Network British Journal of Haematology ·Cristiano Vieira Sobrinho, Claire Mauduit, Juliette Fontaine, Estelle Bourbon, Pierre Sujobert, Sarah Huet, Lucile Baseggio, Sandrine Hayette, Camille Laurent, Emmanuel Bachy, Hervé Ghesquières, Catherine Thiéblemont, Gilles Salles, Alexandra Traverse‐Glehen	2021	8
18	Clinical characteristics and outcomes of relapsed follicular lymphoma after autologous stem cell transplantation in the rituximab era Hematological Oncology ·Pierre Sesques, Jessie Bourcier, Camille Golfier, Laure Lebras, Emmanuelle Nicolas‐Virelizier, Maya Hacini, Stuart R. McGill, Laurent Voillat, Emmanuel Bachy, Alexandra Traverse‐Glehen, Philippe Moreau, Laurent Martin, D. Tsernoglou, Olivier Casasnovas, Steven Le Gouill, Gilles Salles, Hervé Ghesquières	2020	4
19	Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia Blood ·Philipp B. Staber, Marco Herling, Mar Bellido, Д. Е. Федоров, Matthew S. Davids, Tapan M. Kadia, Andrei R. Shustov, Olivier Tournilhac, Emmanuel Bachy, Francesco Zaja, Kimmo Porkka, Gregor Hoermann, Ingrid Simonitsch‐Klupp, Claudia Haferlach, Stefan Kubicek, Marius E. Mayerhoefer, Georg Hopfinger, Ulrich Jaeger, Claire Dearden	2019	67
20	Long-Term Follow-Up of Patients With Newly Diagnosed Follicular Lymphoma in the Prerituximab Era: Effect of Response Quality on Survival—A Study From the Groupe d'Etude des Lymphomes de l'Adulte Journal of Clinical Oncology ·Emmanuel Bachy, Pauline Brice, Richard Delarue, Nicole Brousse, Corinne Haïoun, Steven Le Gouill, Alain Delmer, Dominique Bordessoule, Hervé Tilly, Bernadette Corront, Christian Allard, Charles Foussard, André Bosly, Bertrand Coiffier, Christian Gisselbrecht, Philippe Solal‐Céligny, Gilles Salles	2009	50

About Emmanuel Bachy

Emmanuel Bachy is a scholar working on Pathology and Forensic Medicine, Oncology, Genetics, Immunology and Dermatology, having authored 185 papers that have together received 2.3k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (105 papers), CAR-T cell therapy research (70 papers), Chronic Lymphocytic Leukemia Research (34 papers), Viral-associated cancers and disorders (28 papers), Immune Cell Function and Interaction (13 papers), Cutaneous lymphoproliferative disorders research (11 papers), Biosimilars and Bioanalytical Methods (11 papers) and CNS Lymphoma Diagnosis and Treatment (10 papers). The work is most often cited by research in Pathology and Forensic Medicine (1.2k citations), Oncology (1.3k citations), Genetics (450 citations), Hematology (235 citations) and Immunology (379 citations). Emmanuel Bachy has collaborated with scholars based in France, United States and Switzerland. Frequent co-authors include Gilles Salles, Hervé Ghesquières, Franck Morschhauser, Catherine Thiéblemont, Olivier Hermine, Alexandra Traverse‐Glehen, Guillaume Cartron, Clémentine Sarkozy, Michael Dickinson and Olivier Casasnovas. Their work appears in journals such as Blood, Hematological Oncology, Journal of Clinical Oncology, HemaSphere and Blood Advances.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact